Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...
The pill, gepotidacin, will be sold under the brand name Blujepa and is expected to be available in the second half of 2025.
Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.
The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for ...
If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...
GSK’s pill, the first oral antibiotic for urinary tract infections in almost 30 years, comes as bacteria are increasingly ...
On March 25, the U.S. Food and Drug Administration (FDA) approved the first new antibiotic to treat UTIs in 30 years. The ...
A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...
GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...
This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...
The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections, the first such drug ...
March 26, 2025 — The FDA has approved a new medication to treat uncomplicated urinary tract infections in women and girls aged 12 or older. It is the first in a new class of oral antibiotics ...